Heart failure: Advanced development in genetics and epigenetics

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Yang, Jian ^a   Xu, Wei Wei ^a   Hu, Shen Jiang ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; MICRORNA; GENETIC MARKER;

CHROMATIN ASSEMBLY AND DISASSEMBLY; CONGESTIVE CARDIOMYOPATHY; DNA METHYLATION; EPIGENETICS; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HEART FAILURE; HEART RIGHT VENTRICLE DYSPLASIA; HISTONE MODIFICATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; REVIEW; GENETIC EPIGENESIS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; MUTATION; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; TRENDS;

EPIGENESIS, GENETIC; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEART FAILURE; HUMANS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84928471445     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/352734     Document Type: Review

References (113)

1. A. S. Go, D. Mozaffarian, V. L. Roger et al. , "Heart disease and stroke statistics-2014 update: a report from the American Heart Association, " Circulation, vol. 129, no. 3, pp. e28-e292, 2014.
2. C. W. Yancy, M. Jessup, B. Bozkurt et al. , "2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, " Circulation, vol. 128, no. 16, pp. 1810-1852, 2013.
3. P. Elliott, B. Andersson, E. Arbustini et al. , "Classification of the cardiomyopathies: a position statement fromthe european society of cardiology working group onmyocardial and pericardial diseases, " European Heart Journal, vol. 29, no. 2, pp. 270-276, 2008.
4. A. Posafalvi, J. C. Herkert, R. J. Sinke et al. , "Clinical utility gene card for: dilated cardiomyopathy (CMD), " European Journal of Human Genetics, vol. 21, no. 10, 2013.
5. P. Teekakirikul, M. A. Kelly, H. L. Rehm, N. K. Lakdawala, and B. H. Funke, "Inherited cardiomyopathies: molecular genetics and clinical genetic testing in the postgenomic era, " The Journal of Molecular Diagnostics, vol. 15, no. 2, pp. 158-170, 2013.
6. W. P. Te Rijdt, J. D. H. Jongbloed, R. A. de Boer et al. , "Clinical utility gene card for: arrhythmogenic right ventricular cardiomyopathy (ARVC), " European Journal of Human Genetics, vol. 22, no. 2, 2014.
7. R. E. Hershberger and J. D. Siegfried, "Update 2011: clinical and genetic issues in familial dilated cardiomyopathy, " Journal of the American College of Cardiology, vol. 57, no. 16, pp. 1641-1649, 2011.
8. P. Garcia-Pavia, M. Cobo-Marcos, G. Guzzo-Merello et al. , "Genetics in dilated cardiomyopathy, " Biomarkers in Medicine, vol. 7, no. 4, pp. 517-533, 2013.
9. D. S. Herman, L. Lam, M. R. G. Taylor et al. , "Truncations of titin causing dilated cardiomyopathy, "The New England Journal of Medicine, vol. 366, no. 7, pp. 619-628, 2012.
10. K. Y. van Spaendonck-Zwarts, A. Posafalvi, M. P. van den Berg et al. , "Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy, " European Heart Journal, vol. 35, no. 32, pp. 2165-2173, 2014.
11. J. L. Theis, K. M. Sharpe, M. E. Matsumoto et al. , "Homozygosity mapping and exome sequencing reveal GATAD1 mutation in autosomal recessive dilated cardiomyopathy, " Circulation: Cardiovascular Genetics, vol. 4, no. 6, pp. 585-594, 2011.
12. Z. Liu, W. Li, X. Ma et al. , "Essential role of the zinc finger transcription factor casz1 for Mammalian cardiac morphogenesis and development, "The Journal of Biological Chemistry, vol. 289, no. 43, pp. 29801-29816, 2014.
13. P. Elliott and W. J. McKenna, "Hypertrophic cardiomyopathy, " The Lancet, vol. 363, no. 9424, pp. 1881-1891, 2004.
14. E. Biagini, I. Olivotto, M. Iascone et al. , "Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy, " The American Journal of Cardiology, vol. 114, no. 5, pp. 769-776, 2014.
15. H. Morita, H. L. Rehm, A. Menesses et al. , "Shared genetic causes of cardiac hypertrophy in children and adults, " The New England Journal of Medicine, vol. 358, no. 18, pp. 1899-1908, 2008.
16. H. Morita, R. Nagai, J. G. Seidman, and C. E. Seidman, "Sarcomere gene mutations in hypertrophy and heart failure, " Journal of Cardiovascular Translational Research, vol. 3, no. 4, pp. 297-303, 2010.
17. L. R. Lopes and P. M. Elliott, "Genetics of heart failure, " Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1832, no. 12, pp. 2451-2461, 2013.
18. Z. Liu, Y. Song, D. Li et al. , "The novel mitochondrial 16S rRNA 2336T>C mutation is associated with hypertrophic cardiomyopathy, " Journal of Medical Genetics, vol. 51, no. 3, pp. 176-184, 2014.
19. S. Sen-Chowdhry, R. D. Morgan, J. C. Chambers, and W. J. McKenna, "Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment, " Annual Review ofMedicine, vol. 61, pp. 233-253, 2010.
20. A. Azaouagh, S. Churzidse, T. Konorza, and R. Erbel, "Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update, " Clinical Research in Cardiology, vol. 100, no. 5, pp. 383-394, 2011.
21. A. M. Lahtinen, A. S. Havulinna, P. A. Noseworthy et al. , "Prevalence of arrhythmia-associated gene mutations and risk of sudden cardiac death in the Finnish population, " Annals of Medicine, vol. 45, no. 4, pp. 328-335, 2013.
22. F. W. Friedrich, G. Dilanian, P. Khattar et al. , "A novel genetic variant in the transcription factor Islet-1 exerts gain of function on myocyte enhancer factor 2C promoter activity, " European Journal of Heart Failure, vol. 15, no. 3, pp. 267-276, 2013.
23. N. Okudaira, M. Kuwahara, Y. Hirata, Y. Oku, and H. Nishio, "A knock-in mouse model of N-terminal R420W mutation of cardiac ryanodine receptor exhibits arrhythmogenesis with abnormal calcium dynamics in cardiomyocytes, " Biochemical and Biophysical Research Communications, vol. 452, no. 3, pp. 665-668, 2014.
24. V. Siragam, X. Cui, S. Masse et al. , "TMEM43 mutation p. S358L alters intercalated disc protein expression and reduces conduction velocity in arrhythmogenic right ventricular cardiomyopathy, " PLoSONE, vol. 9, no. 10, Article IDe109128, 2014.
25. S. Sen-Chowdhry, P. Syrris, A. Pantazis, G. Quarta, W. J. McKenna, and J. C. Chambers, "Mutational heterogeneity, modifier genes, and environmental influences contribute to phenotypic diversity of arrhythmogenic cardiomyopathy, " Circulation: Cardiovascular Genetics, vol. 3, no. 4, pp. 323-330, 2010.
26. H. Watkins, H. Ashrafian, and C. Redwood, "Inherited cardiomyopathies, " The New England Journal ofMedicine, vol. 364, no. 17, pp. 1643-1656, 2011.
27. N. G. Mahon, R. T. Murphy, C. A. MacRae, A. L. P. Caforio, P. M. Elliott, and W. J. McKenna, "Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease, " Annals of InternalMedicine, vol. 143, no. 2, pp. 108-115, 2005.
28. Y. M. Hoedemaekers, K. Caliskan, M. Michels et al. , "The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular noncompaction cardiomyopathy, " Circulation: Cardiovascular Genetics, vol. 3, no. 3, pp. 232-239, 2010.
29. J.-R. Bao, J.-Z. Wang, Y. Yao et al. , "Screening of pathogenic genes in Chinese patients with arrhythmogenic right ventricular cardiomyopathy, " Chinese Medical Journal, vol. 126, no. 22, pp. 4238-4241, 2013.
30. E. Gandjbakhch, A. Vite, F. Gary et al. , "Screening of genes encoding junctional candidates in arrhythmogenic right ventricular cardiomyopathy/dysplasia, " Europace, vol. 15, no. 10, pp. 1522-1525, 2013.
31. L. Mestroni and M. R. G. Taylor, "Genetics and genetic testing of dilated cardiomyopathy: a new perspective, " Discovery Medicine, vol. 15, no. 80, pp. 43-49, 2013.
32. D. P. Judge, "Use of genetics in the clinical evaluation of cardiomyopathy, " The Journal of the AmericanMedical Association, vol. 302, no. 22, pp. 2471-2476, 2009.
33. N. Hofman, I. van Langen, and A. A. M. Wilde, "Genetic testing in cardiovascular diseases, " Current Opinion in Cardiology, vol. 25, no. 3, pp. 243-248, 2010.
34. P. Charron, M. Arad, E. Arbustini et al. , "Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of CardiologyWorking Group onMyocardial and Pericardial Diseases, " European Heart Journal, vol. 31, no. 22, pp. 2715-2726, 2010.
35. F. I. Marcus, S. Edson, and J. A. Towbin, "Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians, " Journal of the American College of Cardiology, vol. 61, no. 19, pp. 1945-1948, 2013.
36. D. J. Tester and M. J. Ackerman, "Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice, " Circulation, vol. 123, no. 9, pp. 1021-1037, 2011.
37. J. S. Ware, A. M. Roberts, and S. A. Cook, "Next generation sequencing for clinical diagnostics and personalised medicine: implications for the next generation cardiologist, " Heart, vol. 98, no. 4, pp. 276-281, 2012.
38. T. Vrijenhoek, K. Kraaijeveld, M. Elferink et al. , "Nextgeneration sequencing-based genome diagnostics across clinical genetics centers: implementation choices and their effects, " European Journal of Human Genetics, 2015.
39. B. J. Maron, T. S. Haas, and J. S. Goodman, "Hypertrophic cardiomyopathy: one gene-but many phenotypes, " American Journal of Cardiology, vol. 113, no. 10, pp. 1772-1773, 2014.
40. S. P. Page, S. Kounas, P. Syrris et al. , "Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome, " Circulation: Cardiovascular Genetics, vol. 5, no. 2, pp. 156-166, 2012.
41. F. Pasquale, P. Syrris, J. P. Kaski, J. Mogensen, W. J. McKenna, and P. Elliott, "Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene, " Circulation: CardiovascularGenetics, vol. 5, no. 1, pp. 10-17, 2012.
42. B. Bauce, A. Nava, G. Beffagna et al. , "Multiple mutations in desmosomal proteins encoding genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia, " Heart Rhythm, vol. 7, no. 1, pp. 22-29, 2010.
43. F. Girolami, C. Y. Ho, C. Semsarian et al. , "Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations, " Journal of the American College of Cardiology, vol. 55, no. 14, pp. 1444-1453, 2010.
44. I. Olivotto, F. Girolami, M. J. Ackerman et al. , "Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy, "Mayo Clinic Proceedings, vol. 83, no. 6, pp. 630-638, 2008.
45. I. Olivotto, F. Girolami, R. Sciagr et al. , "Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations, " Journal of the American College of Cardiology, vol. 58, no. 8, pp. 839-848, 2011.
46. S. Sen-Chowdhry, P. Syrris, A. Pantazis, G. Quarta, W. J. McKenna, and J. C. Chambers, "Mutational heterogeneity, modifier genes, and environmental influences contribute to phenotypic diversity of arrhythmogenic cardiomyopathy, " Circulation: Cardiovascular Genetics, vol. 3, no. 4, pp. 323-330, 2010.
47. L. Ho and G. R. Crabtree, "Chromatin remodelling during development, " Nature, vol. 463, no. 7280, pp. 474-484, 2010.
48. K. Ohtani and S. Dimmeler, "Epigenetic regulation of cardiovascular differentiation, " Cardiovascular Research, vol. 90, no. 3, pp. 404-412, 2011.
49. C. P. Chang and B. G. Bruneau, "Epigenetics and cardiovascular development, " Annual Review of Physiology, vol. 74, pp. 41-68, 2012.
50. P. Han, C. T. Hang, J. Yang, and C.-P. Chang, "Chromatin remodeling in cardiovascular development and physiology, " Circulation Research, vol. 108, no. 3, pp. 378-396, 2011.
51. C. T. Hang, J. Yang, P. Han et al. , "Chromatin regulation by Brg1 underlies heart muscle development and disease, " Nature, vol. 466, no. 7302, pp. 62-67, 2010.
52. S. Saxonov, P. Berg, and D. L. Brutlag, "A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1412-1417, 2006.
53. A. M. Deaton and A. Bird, "CpG islands and the regulation of transcription, " Genes & Development, vol. 25, no. 10, pp. 1010-1022, 2011.
54. M. Movassagh, M.-K. Choy, D. A. Knowles et al. , "Distinct epigenomic features in end-stage failing human hearts, " Circulation, vol. 124, no. 22, pp. 2411-2422, 2011.
55. S. Haider, L. Cordeddu, E. Robinson et al. , "The landscape of DNA repeat elements in human heart failure, " Genome Biology, vol. 13, no. 10, article R90, 2012.
56. T. F. Whayne, "Epigenetics in the development, modification, and prevention of cardiovascular disease, " Molecular Biology Reports, vol. 42, no. 4, pp. 765-776, 2015.
57. D. Xiao, C. Dasgupta, M. Chen et al. , "Inhibition ofDNAmethylation reverses norepinephrine-induced cardiac hypertrophy in rats, " Cardiovascular Research, vol. 101, no. 3, pp. 373-382, 2014.
58. C. J. Watson, P. Collier, I. Tea et al. , "Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype, " Human Molecular Genetics, vol. 23, no. 8, pp. 2176-2188, 2014.
59. H. Tao, J. J. Yang, Z. W. Chen et al. , "DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2, " Toxicology, vol. 323, pp. 42-50, 2014.
60. E. Orenes-Pinero, S. Montoro-Garc, J. V. Patel, M. Valds, F. Mar, and G. Y. H. Lip, "Role of microRNAs in cardiac remodelling: new insights and future perspectives, " International Journal of Cardiology, vol. 167, no. 5, pp. 1651-1659, 2013.
61. S. Turdi, W. Sun, Y. Tan, X. Yang, L. Cai, and J. Ren, "Inhibition of DNA methylation attenuates low-dose cadmium-induced cardiac contractile and intracellular Ca2+ anomalies, " Clinical and Experimental Pharmacology & Physiology, vol. 40, no. 10, pp. 706-712, 2013.
62. Y. H. Kao, G. S. Lien, T. F. Chao, and Y. J. Chen, "DNA methylation inhibition: a novel therapeutic strategy for heart failure, " International Journal of Cardiology, vol. 176, no. 1, pp. 232-233, 2014.
63. A. G. Rigopoulos and H. Seggewiss, "Hypertrophic cardiomyopathy, " The Lancet, vol. 381, no. 9876, p. 1456, 2013.
64. R. Papait, P. Cattaneo, P. Kunderfranco et al. , "Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 50, pp. 20164-20169, 2013.
65. V. B. Pillai, N. R. Sundaresan, G. Kim et al. , "Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway, " Journal of Biological Chemistry, vol. 285, no. 5, pp. 3133-3144, 2010.
66. B. S. Ferguson, B. C. Harrison, M. Y. Jeong et al. , "Signaldependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 24, pp. 9806-9811, 2013.
67. Y. H. Kao, J. P. Liou, C. C. Chung et al. , "Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure, " International Journal of Cardiology, vol. 168, no. 4, pp. 4178-4183, 2013.
68. H. F. Nural-Guvener, L. Zakharova, J. Nimlos, S. Popovic, D. Mastroeni, and M. A. Gaballa, "HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation, " Fibrogenesis & Tissue Repair, vol. 7, no. 1, p. 10, 2014.
69. M. P. Gupta, S. A. Samant, S. H. Smith, and S. G. Shroff, "HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity, " The Journal of Biological Chemistry, vol. 283, no. 15, pp. 10135-10146, 2008.
70. A. Pedrama, M. Razandi, R. Narayanan, J. T. Dalton, T. A. McKinsey, and E. R. Levin, "Estrogen regulates histone deacetylases to prevent cardiac hypertrophy, " Molecular Biology of the Cell, vol. 24, no. 24, pp. 3805-3818, 2013.
71. R. Teperino, K. Schoonjans, and J. Auwerx, "Histone methyl transferases and demethylases; can they link metabolism and transcription" CellMetabolism, vol. 12, no. 4, pp. 321-327, 2010.
72. R. Kaneda, S. Takada, Y. Yamashita et al. , "Genome-widehistone methylation profile for heart failure, " Genes to Cells, vol. 14, no. 1, pp. 69-77, 2009.
73. M. Hohl, M. Wagner, J.-C. Reil et al. , "HDAC4 controls histone methylation in response to elevated cardiac load, " The Journal of Clinical Investigation, vol. 123, no. 3, pp. 1359-1370, 2013.
74. M. R. Fabian, N. Sonenberg, andW. Filipowicz, "Regulation of mRNA translation and stability by microRNAs, " Annual Review of Biochemistry, vol. 79, pp. 351-379, 2010.
75. J. Krol, I. Loedige, and W. Filipowicz, "The widespread regulation of microRNA biogenesis, function and decay, " Nature Reviews Genetics, vol. 11, no. 9, pp. 597-610, 2010.
76. T. Thum, P. Galuppo, C. Wolf et al. , "MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure, " Circulation, vol. 116, no. 3, pp. 258-267, 2007.
77. S. Ikeda, S. W. Kong, J. Lu et al. , "AlteredmicroRNA expression in human heart disease, " Physiological Genomics, vol. 31, no. 3, pp. 367-373, 2007.
78. C. Sucharov, M. R. Bristow, and J. D. Port, "miRNA expression in the failing human heart: functional correlates, " Journal of Molecular and Cellular Cardiology, vol. 45, no. 2, pp. 185-192, 2008.
79. D. M. Bers, "Cardiac excitation-contraction coupling, " Nature, vol. 415, no. 6868, pp. 198-205, 2002.
80. M. Jessup, B. Greenberg, D. Mancini et al. , "Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulumCa2+-ATPase in patientswith advanced heart failure, " Circulation, vol. 124, no. 3, pp. 304-313, 2011.
81. C. E. Grueter, E. van Rooij, B. A. Johnson et al. , "A cardiac MicroRNA governs systemic energy homeostasis by regulation of MED13, " Cell, vol. 149, no. 3, pp. 671-683, 2012.
82. R. Fiore and G. Schratt, "MicroRNAs in synapse development: tiny molecules to remember, " Expert Opinion on Biological Therapy, vol. 7, no. 12, pp. 1823-1831, 2007.
83. S. Ikeda, A. He, S. W. Kong et al. , "MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin andMef2a genes, "Molecular and Cellular Biology, vol. 29, no. 8, pp. 2193-2204, 2009.
84. Q. Dai, M. Guo, Y. Guo, X. Liu, Y. Liu, and Z. Teng, "A least square method based model for identifying protein complexes in protein-protein interaction network, " BioMed Research International, vol. 2014, Article ID 720960, 9 pages, 2014.
85. E. Van Rooij, L. B. Sutherland, N. Liu et al. , "A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 48, pp. 18255-18260, 2006.
86. T. Hosoda, H. Zheng, M. Cabral-Da-Silva et al. , "Human cardiac stem cell differentiation is regulated by a mircrine mechanism, " Circulation, vol. 123, no. 12, pp. 1287-1296, 2011.
87. S. J. Matkovich, Y. Hu, W. H. Eschenbacher, L. E. Dorn, and G. W. Dorn, "Direct and indirect involvement of MicroRNA-499 in clinical and experimental cardiomyopathy, " Circulation Research, vol. 111, no. 5, pp. 521-531, 2012.
88. G. W. Dorn, S. J. Matkovich, W. H. Eschenbacher, andY. Zhang, "A human 3 miR-499 mutation alters cardiac mRNA targeting and function, " Circulation Research, vol. 110, no. 7, pp. 958-967, 2012.
89. M. Weber, M. B. Baker, J. P. Moore, and C. D. Searles, "MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activity, " Biochemical and Biophysical Research Communications, vol. 393, no. 4, pp. 643-648, 2010.
90. C. Bang, S. Batkai, S. Dangwal et al. , "Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy, "The Journal of Clinical Investigation, vol. 124, no. 5, pp. 2136-2146, 2014.
91. E. Dirkx, M. M. Gladka, L. E. Philippen et al. , "Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure, " Nature Cell Biology, vol. 15, no. 11, pp. 1282-1293, 2013.
92. C. Wahlquist, D. Jeong, A. Rojas-Munoz et al. , "Inhibition of miR-25 improves cardiac contractility in the failing heart, " Nature, vol. 508, no. 7497, pp. 531-535, 2014.
93. E. Bostjancic, N. Zidar, D. Stajer, and D. Glavac, "MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction, " Cardiology, vol. 115, no. 3, pp. 163-169, 2010.
94. A. Carè, D. Catalucci, F. Felicetti et al. , "MicroRNA-133 controls cardiac hypertrophy, " Nature Medicine, vol. 13, no. 5, pp. 613-618, 2007.
95. C. Xu, Y. Lu, Z. Pan et al. , "The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes, " Journal of Cell Science, vol. 124, part 18, p. 3187, 2011.
96. M. Xin, E. N. Olson, and R. Bassel-Duby, "Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair, " Nature Reviews Molecular Cell Biology, vol. 14, no. 8, pp. 529-541, 2013.
97. P. A. da Costa Martins, K. Salic, M. M. Gladka et al. , "MicroRNA-199b targets the nuclear kinase Dyrk1a in an autoamplification loop promoting calcineurin/NFAT signalling, " Nature Cell Biology, vol. 12, no. 12, pp. 1220-1227, 2010.
98. A. Baumgarten, C. Bang, A. Tschirner et al. , "TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy, " International Journal ofCardiology, vol. 168, no. 2, pp. 1447-1452, 2013.
99. I. Volkmann, R. Kumarswamy, N. Pfaff et al. , "MicroRNAmediated epigenetic silencing of sirtuin1 contributes to impaired angiogenic responses, " Circulation Research, vol. 113, no. 8, pp. 997-1003, 2013.
100. V. Oliveira-Carvalho, V. O. Carvalho, M. M. Silva, G. V. Guimarães, and E. A. Bocchi, "MicroRNAs: a new paradigm in the treatment and diagnosis of heart failure" Arquivos Brasileiros de Cardiologia, vol. 98, no. 4, pp. 362-369, 2012.
101. K. L. Ellis, V. A. Cameron, R. W. Troughton, C. M. Frampton, L. J. Ellmers, and A. M. Richards, "Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients, " European Journal of Heart Failure, vol. 15, no. 10, pp. 1138-1147, 2013.
102. L. Qiang, L. Hong, W. Ningfu et al. , "Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients, " International Journal of Cardiology, vol. 168, no. 3, pp. 2082-2088, 2013.
103. F. Varrone, B. Gargano, P. Carullo et al. , "The circulating level of FABP3 is an indirect biomarker of microRNA-1, " Journal of the American College of Cardiology, vol. 61, no. 1, pp. 88-95, 2013.
104. T. Thum, C. Gross, J. Fiedler et al. , "MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts, " Nature, vol. 456, no. 7224, pp. 980-984, 2008.
105. R. L. Montgomery, T. G. Hullinger, H. M. Semus et al. , "Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure, " Circulation, vol. 124, no. 14, pp. 1537-1547, 2011.
106. L. Suckau, H. Fechner, E. Chemaly et al. , "Long-term cardiactargeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy, " Circulation, vol. 119, no. 9, pp. 1241-1252, 2009.
107. A. Castaldi, T. Zaglia, V. di Mauro et al. , "MicroRNA-133 modulates the beta1-adrenergic receptor transduction cascade, " Circulation Research, vol. 115, no. 2, pp. 273-283, 2014.
108. K. Wang, F. Liu, L. Y. Zhou et al. , "The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489, " Circulation Research, vol. 114, no. 9, pp. 1377-1388, 2014.
109. P. Han, W. Li, C. H. Lin et al. , "A long noncoding RNAprotects the heart from pathological hypertrophy, " Nature, vol. 514, no. 7520, pp. 102-106, 2014.
110. A. Dutta, W. Henley, I. A. Lang et al. , "The coronary artery disease-associated 9p21 variant and later life 20-Year survival to cohort extinction, " Circulation: Cardiovascular Genetics, vol. 4, no. 5, pp. 542-548, 2011.
111. K. Yang, K. A. Yamada, A. Y. Patel et al. , "Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support, " Circulation, vol. 129, no. 9, pp. 1009-1021, 2014.
112. R. Kumarswamy, C. Bauters, I. Volkmann et al. , "Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure, " Circulation Research, vol. 114, no. 10, pp. 1569-1575, 2014.
113. K. Wang, B. Long, L. Y. Zhou et al. , "CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation, " Nature Communications, vol. 5, article 3596, 2014.